Review article · 2023 · Open access

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

Mark Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P. Cope and 1 more

Annals of the Rheumatic Diseases, 82(8), 1059–1067 · Published 29 May 2023 · DOI 10.1136/ard-2023-224049

Open PDFView at the publisherCite this paper

In brief

“JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications” is a 2023 review article by Mark Russell and 12 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 184 citations as of 19 November 2026, which puts it in the top 1% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
184
Most cited in
2025 (65)
Field-weighted impact
6.28
References
33
Authors
13

Abstract

OBJECTIVES: To estimate the association of Janus kinase inhibitors (JAKi) with the incidence of malignancy, compared with placebo, tumour necrosis factor (TNF)-α inhibitors (TNFi) and methotrexate. METHODS: Systematic searches of databases were performed, to December 2022, to identify phase II/III/IV randomised clinical trials (RCTs) and long-term extension (LTE) studies of JAKi (tofacitinib, baricitinib, upadacitinib, filgotinib, peficitinib) compared with placebo, TNFi or methotrexate, in adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease or atopic dermatitis. Network and pairwise meta-analyses were performed to estimate incidence rate ratios (IRRs) for malignancy between JAKi and comparators. Bias was assessed using the Cochrane Risk of Bias-2 tool. RESULTS: In 62 eligible RCTs and 16 LTE studies, there were 82 366 person-years of exposure to JAKi, 2924 to placebo, 7909 to TNFi and 1074 to methotrexate. The overall malignancy incidence rate was 1.15 per 100 person-years in RCTs, and 1.26 per 100 person-years across combined RCT and LTE data. In network meta-analyses, the incidence of all malignancies including non-melanomatous skin cancers (NMSCs) was not significantly different between JAKi and placebo (IRR 0.71; 95% CI 0.44 to 1.15) or between JAKi and methotrexate (IRR 0.77; 95% CI 0.35 to 1.68). Compared with TNFi, however, JAKi were associated with an increased incidence of malignancy (IRR 1.50; 95% CI 1.16 to 1.94). Findings were consistent when analysing NMSC only and when analysing combined RCT/LTE data. CONCLUSIONS: JAKi were associated with a higher incidence of malignancy compared with TNFi but not placebo or methotrexate. Cancers were rare events in all comparisons. PROSPERO REGISTRATION NUMBER: CRD42022362630.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Russell, M., Stovin, C., Alveyn, E., Adeyemi, O., Chan, C. K. D., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Annals of the Rheumatic Diseases, 82(8), 1059–1067. https://doi.org/10.1136/ard-2023-224049

MLA 9

Russell, Mark, et al. “JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.” Annals of the Rheumatic Diseases, vol. 82, no. 8, 2023, pp. 1059–1067. https://doi.org/10.1136/ard-2023-224049.

Chicago

Russell, Mark, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A. Adas, et al. 2023. “JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.” Annals of the Rheumatic Diseases 82 (8): 1059–1067. https://doi.org/10.1136/ard-2023-224049.

Harvard

Russell, M. et al. (2023) ‘JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications’, Annals of the Rheumatic Diseases, 82(8), pp. 1059–1067. doi:10.1136/ard-2023-224049.

IEEE

M. Russell et al., “JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications,” Annals of the Rheumatic Diseases, vol. 82, no. 8, pp. 1059–1067, 2023, doi: 10.1136/ard-2023-224049.

BibTeX

@article{russell2023inhibitors,
  title     = {{JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications}},
  author    = {Russell, Mark and Stovin, Christopher and Alveyn, Edward and Adeyemi, Olukemi and Chan, Chun Kit David and Patel, Vishit and Adas, Maryam A. and Atzeni, Fabiola and Ng, Kenrick K H and Rutherford, Andrew I and Norton, Sam and Cope, Andrew P. and Galloway, James Benjamin},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2023},
  volume    = {82},
  number    = {8},
  pages     = {1059--1067},
  doi       = {10.1136/ard-2023-224049},
  url       = {https://doi.org/10.1136/ard-2023-224049}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20231313
20245353
20256565
20265353

Its field-weighted citation impact is 6.28: it has been cited 6.28 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • JAK inhibitors
  • cancer risk
  • cancer incidence
  • tumor necrosis factor inhibitors
  • methotrexate
  • tofacitinib
  • baricitinib
  • upadacitinib

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Russell, M., Stovin, C., Alveyn, E., Adeyemi, O., Chan, C. K. D., Patel, V., Adas, M. A., Atzeni, F., Ng, K. K. H., Rutherford, A. I., Norton, S., Cope, A. P., & Galloway, J. B. (2023). JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Annals of the Rheumatic Diseases, 82(8), 1059–1067. https://doi.org/10.1136/ard-2023-224049

How many times has this paper been cited?

184 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Mark Russell, Christopher Stovin, Edward Alveyn, Olukemi Adeyemi, Chun Kit David Chan, Vishit Patel, Maryam A. Adas, Fabiola Atzeni, Kenrick K H Ng, Andrew I Rutherford, Sam Norton, Andrew P. Cope and 1 more.

What is the DOI of this paper?

10.1136/ard-2023-224049, permanently at https://doi.org/10.1136/ard-2023-224049. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.